These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3148262)

  • 21. [Streptococcal toxic shock syndrome or Kawasaki disease? Two case studies of children with group A streptococcal pneumonia empyema].
    Bosland A; Arlaud K; Rousset-Rouvière C; Fouilloux V; Paut O; Dubus JC; Bosdure E
    Arch Pediatr; 2011 Dec; 18(12):1310-4. PubMed ID: 22041597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous Kawasaki disease in group A streptococcal pharyngitis.
    Ryan ME; McGregor S; Turkewitz D
    Clin Pediatr (Phila); 1993 Aug; 32(8):510-1. PubMed ID: 8403755
    [No Abstract]   [Full Text] [Related]  

  • 23. [Study on the etiology of Kawasaki disease based on the changes in symptomatology and morbidity among various age groups--on validity of the streptococcal infection theory].
    Yamamoto T
    Nihon Rinsho; 1983 Sep; 41(9):1994-2004. PubMed ID: 6663737
    [No Abstract]   [Full Text] [Related]  

  • 24. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.
    Abinun M; Cant AJ
    Lancet; 1994 Jan; 343(8892):300. PubMed ID: 7905129
    [No Abstract]   [Full Text] [Related]  

  • 25. Possible role of Streptococcus pyogenes in mucocutaneous lymph node syndrome. IV. Immunological tolerance following exposure of neonatal mice to live attenuated strains of Streptococcus pyogenes.
    Akiyama T; Osawa N; Yashiro K
    Acta Paediatr Jpn; 1987 Jun; 29(3):426-32. PubMed ID: 3144872
    [No Abstract]   [Full Text] [Related]  

  • 26. [THE DIAGNOSTIC APPROACHES TO VERIFICATION OF STREPTOCOCCUS INFECTION IN PATIENTS WITH INFECTIOUS MONONUCLEOSIS].
    Kim MA; Labushkina AV; Simovanian EN; Kharseeva GG
    Klin Lab Diagn; 2015 Nov; 60(11):62-5. PubMed ID: 26999869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modeling on streptolysin-O of multidrug resistant Streptococcus pyogenes and computer aided screening and in vitro assay for novel herbal inhibitors.
    Skariyachan S; Narayan NS; Aggimath TS; Nagaraj S; Reddy MS; Narayanappa R
    Curr Comput Aided Drug Des; 2014 Mar; 10(1):59-74. PubMed ID: 24694051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kawasaki disease and toxic shock syndrome--at last the etiology is clear?
    Curtis N
    Adv Exp Med Biol; 2004; 549():191-200. PubMed ID: 15250533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiotoxicity of streptolysin O of group A and group C haemolytic streptococci.
    Gupta RK; Gupta S
    Indian J Pathol Microbiol; 1986 Jul; 29(3):249-54. PubMed ID: 3546111
    [No Abstract]   [Full Text] [Related]  

  • 30. Kawasaki syndrome associated with group A streptococcal and Epstein-Barr virus co-infections.
    Barton M; Melbourne R; Morais P; Christie C
    Ann Trop Paediatr; 2002 Sep; 22(3):257-60. PubMed ID: 12369491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary aneurysms in a patient with atypical Kawasaki syndrome and a streptococcal infection.
    Reller M; DeCristofaro J; Schwartz DC
    Pediatr Cardiol; 1984; 5(3):205-7. PubMed ID: 6397731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kawasaki disease associated with streptococcal infection within a family.
    Anderson DG; Warner G; Barlow E
    J Paediatr Child Health; 1995 Aug; 31(4):355-7. PubMed ID: 7576898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Streptococcal pyrogenic exotoxin A, streptolysin O, exoenzymes, serotype and biotype profiles of Streptococcus pyogenes isolates from patients with toxic shock syndrome and other severe infections.
    Müller-Alouf H; Geoffroy C; Geslin P; Bouvet A; Felten A; Günther E; Ozegowski JH; Alouf JE
    Zentralbl Bakteriol; 1997 Oct; 286(3):421-33. PubMed ID: 9361388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxin-mediated streptococcal and staphylococcal disease.
    Manders SM
    J Am Acad Dermatol; 1998 Sep; 39(3):383-98; quiz 399-400. PubMed ID: 9738772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [IMMUNOLOGICAL STUDIES ON JUVENILE CARRIERS OF STREPTOCOCCI GROUP A].
    PAKULA Z; CARAVANO R
    Reumatologia; 1964; 2():197-207. PubMed ID: 14229152
    [No Abstract]   [Full Text] [Related]  

  • 36. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes.
    Sawai J; Hasegawa T; Kamimura T; Okamoto A; Ohmori D; Nosaka N; Yamada K; Torii K; Ohta M
    Antimicrob Agents Chemother; 2007 Feb; 51(2):461-7. PubMed ID: 17101685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [DETERMINATION OF STREPTOLYSIN O AND PROTEINASE IN GROUP A STREPTOCOCCI ISOLATED FROM CARRIERS AND FROM PATIENTS].
    BURANSKY J; STEFANOVIC J
    Bratisl Lek Listy; 1964; 44():263-8. PubMed ID: 14139947
    [No Abstract]   [Full Text] [Related]  

  • 38. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
    Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
    Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. THE TOXIC ACTION OF PREPARATIONS CONTAINING THE OXYGEN-LABILE HEMOLYSIN OF STREPTOCOCCUS PYOGENES : III. INDUCTION IN MICE OF TEMPORARY RESISTANCE TO THE LETHAL EFFECT OF THE TOXIN.
    Bernheimer AW; Cantoni GL
    J Exp Med; 1947 Aug; 86(3):193-202. PubMed ID: 19871670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible role of Streptococcus pyogenes in mucocutaneous lymph node syndrome. III Electron microscopic observations on group A hemolytic streptococci inoculated into mice.
    Akiyama T; Osawa N; Nakasato K; Yamashina S; Yamamoto N; Tamaki H; Yashiro K
    Acta Paediatr Jpn; 1987 Jun; 29(3):417-25. PubMed ID: 3144871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.